Clinical Trial

Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 7, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with relapsed/refractory Neuroblastoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-20.
Status change: Enrolling by Invitation → Recruiting 2025-02-06
Trial Details
NCT Number NCT06751134
Lead Sponsor Nanjing Children's Hospital
Conditions Neuroblastoma, Recurrent, Refractory
Enrollment 12 participants
Start Date 2024-12-28
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-07